Cellectis' Operating Revenues Slide 8 Percent in First Half of 2013 | GenomeWeb

NEW YORK (GenomeWeb News) – Genome engineering firm Cellectis on Thursday reported that its total operating revenues slipped 8 percent year over year during the first half of 2013.

For the first six months of the year, the Paris-based firm brought in €6.9 million ($9.4 million) in operating revenues, compared to €7.5 million during the first half of 2012. Operating revenues for the recently completed period comprised €2.8 million in sales, down from €3.1 million a year ago, and €4.1 million in other operating revenues, down from €4.4 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."